MV Capital Management Inc. Buys New Stake in Gilead Sciences, Inc. $GILD

MV Capital Management Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 7,568 shares of the biopharmaceutical company’s stock, valued at approximately $929,000.

Several other hedge funds have also bought and sold shares of the stock. Paulson Wealth Management Inc. grew its position in shares of Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares in the last quarter. Essex Financial Services Inc. boosted its stake in Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 71 shares during the last quarter. Alpha Cubed Investments LLC boosted its stake in Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after buying an additional 75 shares during the last quarter. Personal CFO Solutions LLC grew its holdings in Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after buying an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.3%

GILD opened at $123.76 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock’s 50 day moving average price is $132.01 and its 200-day moving average price is $134.29. Gilead Sciences, Inc. has a one year low of $104.46 and a one year high of $157.29. The stock has a market cap of $153.66 billion, a price-to-earnings ratio of 16.86 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent research reports. Truist Financial reaffirmed a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Leerink Partners dropped their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Royal Bank Of Canada restated a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 20th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a report on Tuesday. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $158.41.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the sale, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the transaction, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 68,000 shares of company stock valued at $8,930,150. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.